Login to Your Account

Clinic Roundup

Wednesday, October 23, 2013
• Bioalliance Pharma SA, of Paris, said the international independent board of experts’ data and safety monitoring board in charge of the safety profile of the ReLive Phase III trial unanimously recommended continuing the study without modification for the third time since the trial’s start.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription